- Home
- MRNA vs CTVA Comparison
MRNA vs CTVA Comparison
Compare MRNA & CTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRNA | CTVA |
|---|---|---|
| Founded | 2010 | 1802 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Farming/Seeds/Milling |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6B | 56.6B |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MRNA | CTVA |
|---|---|---|
| Price | $198.47 | $78.29 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 16 |
| Target Price | $34.27 | ★ $84.13 |
| AVG Volume (30 Days) | ★ 13.5M | 3.3M |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 0.91% |
| EPS Growth | 21.77 | ★ 23.08 |
| EPS | N/A | ★ 2.80 |
| Revenue | ★ $19,263,000,000.00 | $17,401,000,000.00 |
| Revenue This Year | $9.36 | $6.09 |
| Revenue Next Year | $15.43 | $3.28 |
| P/E Ratio | ★ N/A | $27.76 |
| Revenue Growth | ★ 4.29 | 2.92 |
| 52 Week Low | $22.28 | $60.54 |
| 52 Week High | $202.67 | $90.97 |
Technical Indicators
Market Signals| Indicator | MRNA | CTVA |
|---|---|---|
| Relative Strength Index (RSI) | 75.87 | 38.57 |
| Support Level | $43.35 | $75.10 |
| Resistance Level | N/A | $81.07 |
| Average True Range (ATR) | 11.47 | 2.23 |
| MACD | 2.59 | -0.63 |
| Stochastic Oscillator | 86.71 | 18.60 |
Price Performance
Historical ComparisonAbout MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About CTVA Corteva Inc.
Corteva is an agricultural inputs pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop protection products. Seeds generate the majority of profits with the remainder coming from crop protection products. Corteva plans to spin off its seeds business in late 2026. The seeds business will be named Vylor, while the crop protection business will retain the Corteva name and be a pure-play crop protection company following the divestiture. Corteva operates globally, but around half of revenue comes from North America.